TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$54.21
-0.19 (-0.35%)
▼
5d:
+7.77%
30d:
+38.15%
90d:
+78.03%
WAIT
LOW Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.7/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: TGTX is 10.1% above its trading range ($49.25). Market expects 7.4% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: TGTX is 10.1% above its trading range ($49.25). Market expects 7.4% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.58
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$53.14
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $54.21, which is considered extended relative to its 30-day fair value range of $37.67 to $49.25. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.9) compared to its historical average (15.3). At these levels, the market is pricing in 7.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $41.55, while resistance sits at $57.38.
Market Sentiment: TGTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $48.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $41.55, while resistance sits at $57.38.
Market Sentiment: TGTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $48.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$37.67 -
$49.25
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
42.9%
Protect Your Profits
TGTX is technically overbought (RSI 83). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+10.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 11.8% above Wall St target ($48.00)
- NEUTRAL: PE elevated vs history but 7.4% growth expectation is conservative given 300% recent growth
Trading Range Analysis
30-Day Trading Range
$37.67 -
$49.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$41.55
Resistance Level
$57.38
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.94
Wall Street Target
$48.00
(-11.8%)
Revenue Growth (YoY)
69.6%
Earnings Growth (YoY)
300.0%
Profit Margin
66.0%
Valuation Premium vs History
+7.4% premium
PE vs Historical
18.9 vs 15.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.4%
(market-implied from PE analysis)
1-Year Target
$58.43
(+7%)
2-Year Target
$62.75
(+15%)
3-Year Target
$67.39
(+24%)
3-Yr Target (if PE normalizes)
(PE: 19→15)
PE COMPRESSION
$54.44
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 87.1%)
$211.13
(+288%)
Base:
(SPY PE: 18.9, Growth: 87.1%)
$183.60
(+238%)
Bear:
(PE: 15.3, Growth: 87.1%)
$148.31
(+173%)
📈
Valuation based on Current Earnings
Trailing PE: 18.61 | Current EPS (TTM): $2.86
Bull Case
$58.79
(+8%)
Analyst growth 0.4%, PE expands to 20.5
Base Case
$53.45
(-2%)
Market implied 0.4%, PE stable at 18.6
Bear Case
$36.19
(-34%)
Severe decline -20.0%, PE contracts to 15.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
